Epidemiology of Glioblastoma Multiforme-Literature Review

Simple Summary Glioblastoma multiforme (GBM) is one of the most aggressive malignancies, accounting for 14.5% of all central nervous system tumors and 48.6% of malignant central nervous system tumors. The median overall survival (OS) of GBM patients is only 15 months. The aim of this review was to provide an overview of the epidemiology of GBM and factors that may have a significant impact on the risk of GBM. Glioblastoma multiforme (GBM) is one of the most aggressive malignancies, with a median overall survival of approximately 15 months. In this review, we analyze the pathogenesis of GBM, as well as epidemiological data, by age, gender, and tumor location. The data indicate that GBM is the higher-grade primary brain tumor and is significantly more common in men. The risk of being diagnosed with glioma increases with age, and median survival remains low, despite medical advances. In addition, it is difficult to determine clearly how GBM is influenced by stimulants, certain medications (e.g., NSAIDs), cell phone use, and exposure to heavy metals.

Automated summary

Glioblastoma multiforme (GBM) is a highly aggressive malignancy with a median overall survival of approximately 15 months. This review analyzes the pathogenesis and epidemiological data of GBM, including age, gender, and tumor location. The data suggest that GBM is a higher-grade primary brain tumor and is significantly more common in men. Despite advancements in medicine, the risk of being diagnosed with glioma increases with age and median survival remains low. Additionally, the influence of stimulants, certain medications (such as NSAIDs), cell phone use, and exposure to heavy metals on GBM is difficult to determine clearly.